S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   282.00 (-0.05%)
AAPL   146.32 (+0.15%)
MSFT   249.20 (+0.13%)
META   138.87 (-1.01%)
GOOGL   101.40 (-0.24%)
AMZN   121.12 (+0.02%)
TSLA   240.37 (-3.64%)
NVDA   131.97 (+0.23%)
NIO   16.07 (-3.95%)
BABA   84.42 (+0.37%)
AMD   67.84 (-0.09%)
T   15.95 (-0.87%)
MU   54.74 (+1.45%)
CGC   3.06 (-2.55%)
F   12.50 (+1.13%)
GE   67.51 (-0.04%)
DIS   100.72 (-0.71%)
AMC   7.34 (-6.26%)
PYPL   94.01 (+1.31%)
PFE   44.11 (-0.79%)
NFLX   237.30 (-1.43%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   282.00 (-0.05%)
AAPL   146.32 (+0.15%)
MSFT   249.20 (+0.13%)
META   138.87 (-1.01%)
GOOGL   101.40 (-0.24%)
AMZN   121.12 (+0.02%)
TSLA   240.37 (-3.64%)
NVDA   131.97 (+0.23%)
NIO   16.07 (-3.95%)
BABA   84.42 (+0.37%)
AMD   67.84 (-0.09%)
T   15.95 (-0.87%)
MU   54.74 (+1.45%)
CGC   3.06 (-2.55%)
F   12.50 (+1.13%)
GE   67.51 (-0.04%)
DIS   100.72 (-0.71%)
AMC   7.34 (-6.26%)
PYPL   94.01 (+1.31%)
PFE   44.11 (-0.79%)
NFLX   237.30 (-1.43%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   282.00 (-0.05%)
AAPL   146.32 (+0.15%)
MSFT   249.20 (+0.13%)
META   138.87 (-1.01%)
GOOGL   101.40 (-0.24%)
AMZN   121.12 (+0.02%)
TSLA   240.37 (-3.64%)
NVDA   131.97 (+0.23%)
NIO   16.07 (-3.95%)
BABA   84.42 (+0.37%)
AMD   67.84 (-0.09%)
T   15.95 (-0.87%)
MU   54.74 (+1.45%)
CGC   3.06 (-2.55%)
F   12.50 (+1.13%)
GE   67.51 (-0.04%)
DIS   100.72 (-0.71%)
AMC   7.34 (-6.26%)
PYPL   94.01 (+1.31%)
PFE   44.11 (-0.79%)
NFLX   237.30 (-1.43%)
S&P 500   3,783.28 (-0.20%)
DOW   30,273.87 (-0.14%)
QQQ   282.00 (-0.05%)
AAPL   146.32 (+0.15%)
MSFT   249.20 (+0.13%)
META   138.87 (-1.01%)
GOOGL   101.40 (-0.24%)
AMZN   121.12 (+0.02%)
TSLA   240.37 (-3.64%)
NVDA   131.97 (+0.23%)
NIO   16.07 (-3.95%)
BABA   84.42 (+0.37%)
AMD   67.84 (-0.09%)
T   15.95 (-0.87%)
MU   54.74 (+1.45%)
CGC   3.06 (-2.55%)
F   12.50 (+1.13%)
GE   67.51 (-0.04%)
DIS   100.72 (-0.71%)
AMC   7.34 (-6.26%)
PYPL   94.01 (+1.31%)
PFE   44.11 (-0.79%)
NFLX   237.30 (-1.43%)
NASDAQ:NUVA

NuVasive - NUVA Stock Forecast, Price & News

$43.77
-0.63 (-1.42%)
(As of 10/5/2022 03:59 PM ET)
Add
Compare
Today's Range
$42.60
$44.12
50-Day Range
$42.51
$54.02
52-Week Range
$41.33
$62.83
Volume
33,326 shs
Average Volume
634,451 shs
Market Capitalization
$2.28 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$60.91

NuVasive MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.50 Rating Score
Upside/​Downside
38.3% Upside
$60.27 Price Target
Short Interest
Bearish
6.52% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.22mentions of NuVasive in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
13.00%
From $2.23 to $2.52 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.78 out of 5 stars

Medical Sector

911th out of 1,087 stocks

Surgical & Medical Instruments Industry

90th out of 106 stocks

NUVA stock logo

About NuVasive (NASDAQ:NUVA) Stock

NuVasive, Inc., a medical technology company, develops, manufactures, and sells procedural solutions for spine surgery. It provides surgical access instruments, including Maxcess integrated split-blade retractor system that enable less-invasive surgical techniques by minimizing soft tissue disruption during spine surgery; specialized spinal implants to advance spinal fusion by enhancing the osseointegration and biomechanical properties of implant materials, including porous titanium and porous polyetheretherketone; and fixation system that facilitates the preservation and restoration of patient alignment. The company also offers cervical total disc replacement technology for cervical spinal fusion surgery; neuromonitoring systems, which use proprietary software-driven nerve detection and avoidance technology, and its intraoperative neuromonitoring services and support; and Pulse platform, a software ecosystem that integrates multiple hardware technologies into a single, condensed footprint in the operating room. In addition, it provides expandable growing rod implant systems for the treatment of early-onset scoliosis; various biologics that are used to aid in the spinal fusion or bone healing process; Precice, an intramedullary implant device that utilizes the MAGEC technology to non-invasively lengthen the femur and tibia; and onsite and remote monitoring of the neurological systems of patients undergoing spinal and brain-related surgeries. The company sells its products to patients, surgeons, hospitals, and insurers through independent sales agents, directly employed sales personnel, and distributors in the United States and internationally. NuVasive, Inc. was incorporated in 1997 and is headquartered in San Diego, California.

Receive NUVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.

NUVA Stock News Headlines

NuVasive Announces Agenda for Investor Day 2022
NuVasive, Inc. Q2 Earnings Summary
NuVasive (NUVA) Lags Q2 Earnings Estimates
See More Headlines
Receive NUVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NuVasive and its competitors with MarketBeat's FREE daily newsletter.

NUVA Company Calendar

Last Earnings
8/03/2022
Today
10/05/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:NUVA
CUSIP
67070410
Employees
2,900
Year Founded
1997

Price Target and Rating

Average Stock Price Forecast
$60.27
High Stock Price Forecast
$83.00
Low Stock Price Forecast
$53.00
Forecasted Upside/Downside
+39.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
12 Analysts

Profitability

Net Income
$-64,090,000.00
Pretax Margin
-2.96%

Debt

Sales & Book Value

Annual Sales
$1.14 billion
Cash Flow
$4.73 per share
Book Value
$15.37 per share

Miscellaneous

Free Float
51,816,000
Market Cap
$2.28 billion
Optionable
Optionable
Beta
1.09

Social Links


Key Executives

  • Mr. J. Christopher BarryMr. J. Christopher Barry (Age 48)
    CEO & Director
    Comp: $2.93M
  • Mr. Matthew K. Harbaugh (Age 52)
    Exec. VP & CFO
    Comp: $939.39k
  • Mr. Dale A. Wolf (Age 42)
    Sr. VP of Global Operations
    Comp: $679.16k
  • Mr. Nathaniel B. Sisitsky Esq. (Age 47)
    Sr. VP, Gen. Counsel & Corp. Sec.
    Comp: $787.93k
  • Mr. Massimo CalafioreMr. Massimo Calafiore
    Exec. VP & Chief Commercial Officer
  • Mr. Marc Rosenbaum (Age 50)
    VP, Corp. Controller & Chief Accounting Officer
  • Mr. Ryan Donahoe
    Sr. VP & Chief Technology Officer
  • Mr. Johnson Lai
    Chief Information Officer
  • Ms. Juliet C. Cunningham
    VP of Investor Relations
  • Mr. Michael Farrington
    Sr. VP of Corp. Marketing, Brand & Communication













NUVA Stock - Frequently Asked Questions

Should I buy or sell NuVasive stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for NuVasive in the last year. There are currently 1 sell rating, 4 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" NUVA shares.
View NUVA analyst ratings
or view top-rated stocks.

What is NuVasive's stock price forecast for 2022?

12 Wall Street research analysts have issued 1-year price targets for NuVasive's shares. Their NUVA share price forecasts range from $53.00 to $83.00. On average, they expect the company's stock price to reach $60.27 in the next twelve months. This suggests a possible upside of 39.3% from the stock's current price.
View analysts price targets for NUVA
or view top-rated stocks among Wall Street analysts.

How have NUVA shares performed in 2022?

NuVasive's stock was trading at $52.48 on January 1st, 2022. Since then, NUVA stock has decreased by 17.5% and is now trading at $43.27.
View the best growth stocks for 2022 here
.

When is NuVasive's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our NUVA earnings forecast
.

How were NuVasive's earnings last quarter?

NuVasive, Inc. (NASDAQ:NUVA) announced its quarterly earnings results on Wednesday, August, 3rd. The medical device company reported $0.47 EPS for the quarter, missing analysts' consensus estimates of $0.55 by $0.08. The medical device company had revenue of $310.45 million for the quarter, compared to analyst estimates of $305.83 million. NuVasive had a positive trailing twelve-month return on equity of 11.12% and a negative net margin of 3.41%.

How will NuVasive's stock buyback program work?

NuVasive announced that its board has authorized a stock repurchase plan on Tuesday, November 9th 2021, which authorizes the company to repurchase $100,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to buy up to 3.5% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's management believes its stock is undervalued.

What guidance has NuVasive issued on next quarter's earnings?

NuVasive issued an update on its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share (EPS) guidance of $2.15-$2.45 for the period, compared to the consensus EPS estimate of $2.31. The company issued revenue guidance of $1.21 billion-$1.23 billion, compared to the consensus revenue estimate of $1.22 billion.

What is Chris Barry's approval rating as NuVasive's CEO?

59 employees have rated NuVasive Chief Executive Officer Chris Barry on Glassdoor.com. Chris Barry has an approval rating of 88% among the company's employees.

What other stocks do shareholders of NuVasive own?

Based on aggregate information from My MarketBeat watchlists, some companies that other NuVasive investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), Intel (INTC), Alibaba Group (BABA), (MDVN) (MDVN), Micron Technology (MU), Bank of America (BAC), Gilead Sciences (GILD) and Applied Materials (AMAT).

What is NuVasive's stock symbol?

NuVasive trades on the NASDAQ under the ticker symbol "NUVA."

How do I buy shares of NuVasive?

Shares of NUVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is NuVasive's stock price today?

One share of NUVA stock can currently be purchased for approximately $43.27.

How much money does NuVasive make?

NuVasive (NASDAQ:NUVA) has a market capitalization of $2.25 billion and generates $1.14 billion in revenue each year. The medical device company earns $-64,090,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis.

How many employees does NuVasive have?

The company employs 2,900 workers across the globe.

Does NuVasive have any subsidiaries?
The following companies are subsidiares of NuVasive: Biotronic NeuroNetwork, Ellipse Technologies, NuVasive Clinical Services Monitoring Inc., NuVasive Japan KK, NuVasive Specialized Orthopedics Inc., NuVasive Technology International Limited, SafePassage, Simplify Medical, and Vertera Spine.
Read More
How can I contact NuVasive?

NuVasive's mailing address is 7475 LUSK BOULEVARD, SAN DIEGO CA, 92121. The official website for the company is www.nuvasive.com. The medical device company can be reached via phone at (858) 909-1800, via email at investorrelations@nuvasive.com, or via fax at 800-475-9134.

This page (NASDAQ:NUVA) was last updated on 10/5/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.